ATC Group: C03AA01 Bendroflumethiazide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C03AA01 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C03 Diuretics
3 C03A Low-ceiling diuretics, thiazides
4 C03AA Thiazides, plain
5 C03AA01 Bendroflumethiazide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 2.5 mg

Active ingredients in C03AA01

Active Ingredient Description
Bendroflumethiazide

Bendroflumethiazide inhibits the renal tubular absorption of salt and water by its action at the beginning of the distal convoluted tubule. Sodium and chloride ions are excreted in equivalent proportions.

Medicines in this ATC group

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.